
    
      [Double Blind Phase] The primary objective is to compare change in the Average Daily Pain
      Score(ADPS) from baseline to Week 14 in Asian subjects with DPNP receiving DS-5565 versus
      placebo.

      [Open Extension Phase] The objective is to assess the long-term safety and efficacy of
      DS-5565 in subjects with DPNP.
    
  